At the 7th China International Import Expo (CIIE), Chinese firms Beijing Mabworks Biotech Co., Ltd, and KYinno Biotechnology Co., Ltd, have jointly announced a cooperation Memorandum of Understanding (MoU) with global pharmaceutical leader Pfizer (NYSE: PFE). The collaboration focuses on the clinical development of innovative treatment solutions for patients with multiple myeloma, marking Pfizer’s first partnership with domestic biotechs in mainland China since the implementation of its Ignite plan in the country.
Focus on Multiple Myeloma Clinical Development
The MoU signifies a strategic move to advance the clinical development of novel therapies for multiple myeloma, a form of blood cancer that affects plasma cells. This partnership aims to leverage the combined expertise and resources of the companies to improve treatment options and outcomes for patients.
Pfizer Ignite Program Support
Pfizer Ignite, a comprehensive program encompassing preclinical research and development, clinical development, clinical and commercial supply, and production, will play a crucial role in facilitating the collaboration on novel multiple myeloma (MM) product development. The program’s support is expected to accelerate the progress of the partnership’s initiatives.-Fineline Info & Tech
Leave a Reply